- CASE STUDY · BRAND STRATEGY
DOL Mapping for a Dermatology Biologic: Activating 250+ Digital Opinion Leaders Pre-Launch
OneAlphaMed identified, scored, and activated 250+ Digital Opinion Leaders across social platforms to drive pre-launch disease awareness for a novel dermatology biologic — before a single sales rep made a call.
Industry / Specialty
Pharmaceutical & Healthcare
Scale / Audience
15,000+ HCPs
Core Solutions
Co-created Certification
Time to Value
Pan-India Deployment
At a Glance
Industry / Specialty
Dermatology / Immunology
Scale / Audience
250+ DOLs · 1.2M Reach
Core Solutions
DOL Mapping · Social Activation
Time to Value
90-Day Pre-Launch Window
Ready to build your certification engine?
Stop funding clicks. Start building undisputed credibility for your brand today.
- Executive Summary
A pharmaceutical brand preparing to launch a novel biologic for moderate-to-severe atopic dermatitis recognized that the most influential voices in dermatology had migrated from medical congresses to social media platforms. OneAlphaMed deployed a proprietary Digital Opinion Leader (DOL) identification and activation framework — mapping 2,000+ dermatology-adjacent social accounts, scoring them on reach, engagement quality, and scientific credibility, and activating the top 250 for a coordinated pre-launch disease awareness campaign. The result: 1.2 million HCP-verified impressions before launch day, with zero promotional content — entirely through science-led, organically authored DOL posts.
- 01 — The Challenge
The Invisible Pre-Launch Window
Traditional pre-launch medical education strategies reach only the HCPs who attend congresses or respond to MSL visits — missing the fast-growing segment of specialty physicians who form clinical opinions online.
Uncharted DOL Landscape
The brand had no systematic way to identify which dermatologists were generating genuine scientific influence on platforms like Twitter/X, LinkedIn, and Instagram versus those who were merely active. Without a rigorous scoring methodology, any DOL activation risked investing resources in accounts with large followings but negligible clinical credibility or engagement from HCP audiences.
Regulatory Tightrope
Pre-launch social media engagement for a pharmaceutical product sits at the intersection of promotional regulations, platform policies, and medical ethics. Any misstep — including implied product endorsement before regulatory approval — could trigger a compliance action, damage the brand's regulatory standing, and undermine the scientific credibility of the DOLs themselves.
Authenticity vs. Orchestration
The scientific community is acutely sensitive to sponsored content that feels scripted or commercially directed. Any DOL activation that appeared 'pharma-managed' rather than authentically expert-driven would rapidly erode the social credibility of both the DOLs and the brand — defeating the purpose of the strategy entirely.
- 02 — The Approach
The DOL Intelligence & Activation Engine
OneAlphaMed built a proprietary three-stage framework: map, score, and activate — with scientific integrity as the non-negotiable foundation at every step.
Proprietary DOL Mapping & Scoring
OneAlphaMed's data team scraped and analyzed 2,000+ dermatology-adjacent social accounts, scoring each on a composite index of clinical credential verification, audience HCP-composition analysis, engagement authenticity (filtering bot-inflated metrics), scientific content ratio, and peer citation frequency. This produced a ranked shortlist of 250 DOLs with genuinely influential HCP audiences.
Compliant Pre-Launch Scientific Engagement
Rather than briefing DOLs on the product, OneAlphaMed engaged the top 250 DOLs in a series of exclusive, academically-framed disease education roundtables — co-hosted with a national dermatology association — focused on unmet needs in atopic dermatitis management. DOLs were equipped with peer-reviewed data, not promotional messaging, enabling authentic, compliance-safe social commentary.
Coordinated Organic Amplification
OneAlphaMed designed a staggered content calendar — ensuring that DOL posts appeared organically distributed over the 90-day pre-launch window rather than in a single, obviously coordinated burst. Each DOL's content was tailored to their established voice and audience, maintaining authenticity while building collective narrative momentum around the disease area.
Innovation & Value
Science-Led Social Influence at Scale.
The breakthrough was treating DOL activation as a medical education initiative rather than a marketing exercise. By anchoring every engagement in genuinely valuable scientific content — and giving DOLs full editorial autonomy over how they communicated their perspectives — OneAlphaMed created a pre-launch environment where the disease narrative was being shaped by authentic clinical voices, not brand messaging, weeks before the sales force made a single call.
- 03 — The Results
Key Metrics & Performance Data
The DOL activation delivered HCP-verified reach at a scale no traditional pre-launch medical education program could match.
DOLS ACTIVATED
0
+
HCP IMPRESSIONS
0
M
PRE-LAUNCH ADVANTAGE
0
Days
Zero
COMPLIANCE INCIDENTS
- 04 — The Bottom Line
Stakeholder Outcomes
The DOL campaign fundamentally changed the launch environment — ensuring that the dermatology community was primed with disease awareness and unmet need recognition before the first commercial interaction.
For the DOL
Gained access to cutting-edge clinical data and a structured peer learning community ahead of the broader medical community, reinforcing their position as credible scientific voices in their specialty social network — without compromising their independence or scientific integrity.
For the Brand's Medical Affairs Team
Achieved unprecedented pre-launch HCP mindshare in the disease area without a single piece of promotional content. The DOL-generated social conversation significantly reduced the educational burden on the MSL team, who arrived at launch to find HCPs already familiar with the key clinical concepts.
For the Brand
Entered launch day with a measurably more favorable awareness environment than any previous product in the portfolio — with a 40% higher baseline HCP 'unaided disease awareness' score compared to the brand's previous dermatology launch in the same market.
- FAQ
Frequently Asked Questions
Every DOL engagement is structured as medical education, not promotional activity. DOLs receive disease-state data, not product messaging, and all content is generated independently by the DOL. Disclosure of the educational partnership is mandatory and standardized. All engagement protocols are reviewed by the brand's legal, medical, and regulatory teams before activation, and each DOL signs a comprehensive engagement agreement with clear content guardrails.
OneAlphaMed's content calendar deliberately staggers DOL posts across the 90-day window with randomized timing patterns. Each DOL's content brief is individualized to their established voice, audience, and content style — so posts reflect genuinely different perspectives on the same disease topic rather than templated messaging. The staggered, individualized approach is designed to be indistinguishable from organic scientific commentary.
Yes — and this is precisely when it is most valuable. DOL mapping and educational engagement can begin as soon as the disease area strategy is defined, entirely independent of product approval timelines. Disease education, unmet need awareness, and scientific dialogue are not subject to pre-approval promotional restrictions, giving the brand a critical 12–18-month head start in shaping the clinical narrative before any commercial activity begins.